This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.01.064v1 49/16/1722    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mochizuki, M. Articles by Matsuzaki, M. Search for Related Content PubMed PubMed Citation Articles by Mochizuki, M. Articles by Matsuzaki, M.

PRECLINICAL STUDY

Scavenging Free Radicals by Low-Dose Carvedilol Prevents Redox-Dependent Ca²⁺ Leak Via Stabilization of Ryanodine Receptor in Heart Failure

Mamoru Mochizuki, MD^_*, Masafumi Yano, MD, PhD^_*,_*, Tetsuro Oda, MD, PhD^_*, Hiroki Tateishi, MD^_*, Shigeki Kobayashi, MD, PhD^_*, Takeshi Yamamoto, MD, PhD^_*, Yasuhiro Ikeda, MD, PhD^_*, Tomoko Ohkusa, MD, PhD^_*, Noriaki Ikemoto, PhD^, and Masunori Matsuzaki, MD, PhD, FACC^_*

^_* Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine, Ube, Japan
Boston Biomedical Research Institute, Watertown, Massachusetts
Department of Neurology, Harvard Medical School, Boston, Massachusetts

Manuscript received June 12, 2006; revised manuscript received December 11, 2006, accepted January 1, 2007.

^_* Reprint requests and correspondence: Dr. Masafumi Yano, Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan. (Email: yanoma{at}yamaguchi-u.ac.jp).

Objectives: We investigated whether defective intracellular Ca²⁺ handling is corrected by carvedilol in heart failure.

Background: In heart failure, the interaction between the N-terminal and central domains of the ryanodine receptor (RyR), the domains where many mutations have been found in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), is defective, as shown in our recent report.

Methods: Sarcoplasmic reticulum vesicles were isolated from canine left ventricular muscle (normal or 4-weeks rapid ventricular pacing). The RyR was labeled with the fluorescent conformational probe methylcoumarin acetate (MCA) with DPc10 (a synthetic peptide corresponding to Gly²⁴⁶⁰-Pro²⁴⁹⁵ of RyR, one of the mutable domains in CPVT) as a site-direction carrier.

Results: Normal cardiac function was well preserved in carvedilol-treated/paced dogs (CV+) but not in the untreated/paced dogs (CV–). In CV–, the interdomain interaction within RyR was defective (i.e., in an unzipped state), as determined by the fluorescence quenching technique. However, in CV+, the domain interaction remained normal (i.e., in a zipped state). In CV–, oxidative stress of RyR (reduction in the number of free thiols) was severe, but it was negligible in CV+. In (CV–) failing cardiomyocytes, incubation with low-dose CV (30 nmol/l), which eliminated intracellular reactive oxygen species with no acute effect on cell shortening, markedly improved the contractile function and Ca²⁺ transient. However, after domain unzipping by DPc10, CV was without effect.

Conclusions: Carvedilol, at a concentration that is sufficient to produce antioxidant effect, improves the intracellular Ca²⁺ handling and contractile dysfunction by correcting defective interdomain interaction within the RyR in the failing heart.

Abbreviations and Acronyms   CPVT = catecholaminergic polymorphic ventricular tachycardia   CV = carvedilol   DCFH-DA = 2',7'-dichlorofluorescin diacetate   DPc10 = a synthetic peptide corresponding to Gly2460-Pro2495 of ryanodine receptor   LV = left ventricle/ventricular   mBB = monobromobimane   MCA = methylcoumarin acetate   PKA = protein kinase A   PLB = phospholamban   ROS = reactive oxygen species   RV = rapid ventricular   RyR = ryanodine receptor   SIN-1 = 3-morpholinosydnonimine   SR = sarcoplasmic reticulum

This article has been cited by other articles:

				T. Suetomi, M. Yano, H. Uchinoumi, M. Fukuda, A. Hino, M. Ono, X. Xu, H. Tateishi, S. Okuda, M. Doi, et al. Mutation-Linked Defective Interdomain Interactions Within Ryanodine Receptor Cause Aberrant Ca2+ Release Leading to Catecholaminergic Polymorphic Ventricular Tachycardia Circulation, August 9, 2011; 124(6): 682 - 694. [Abstract] [Full Text] [PDF]

				S. Kobayashi, T. Susa, T. Tanaka, Y. Wada, S. Okuda, M. Doi, T. Nao, Y. Yoshiga, J. Yamada, T. Okamura, et al. Urinary 8-hydroxy-2'-deoxyguanosine reflects symptomatic status and severity of systolic dysfunction in patients with chronic heart failure Eur J Heart Fail, January 1, 2011; 13(1): 29 - 36. [Abstract] [Full Text] [PDF]

				H. J. Bogaard, R. Natarajan, S. Mizuno, A. Abbate, P. J. Chang, V. Q. Chau, N. N. Hoke, D. Kraskauskas, M. Kasper, F. N. Salloum, et al. Adrenergic Receptor Blockade Reverses Right Heart Remodeling and Dysfunction in Pulmonary Hypertensive Rats Am. J. Respir. Crit. Care Med., September 1, 2010; 182(5): 652 - 660. [Abstract] [Full Text] [PDF]

				R. J. van Oort, J. L. Respress, N. Li, C. Reynolds, A. C. De Almeida, D. G. Skapura, L. J. De Windt, and X. H.T. Wehrens Accelerated Development of Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction in an RyR2-R176Q Knockin Mouse Model Hypertension, April 1, 2010; 55(4): 932 - 938. [Abstract] [Full Text] [PDF]

				T. R. Shannon and W. Y.W. Lew Diastolic Release of Calcium From the Sarcoplasmic Reticulum: A Potential Target for Treating Triggered Arrhythmias and Heart Failure J. Am. Coll. Cardiol., May 26, 2009; 53(21): 2006 - 2008. [Full Text] [PDF]